Cargando…
Can a physician predict the clinical response to first-line immunomodulatory treatment in relapsing–remitting multiple sclerosis?
BACKGROUND: Decreased relapse rate and slower disease progression have been reported with long-term use of immunomodulatory treatments (IMTs, interferon beta or glatiramer acetate) in relapsing–remitting multiple sclerosis. There are, however, patients who do not respond to such treatments, and they...
| Autores principales: | , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Dove Medical Press
2012
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3484901/ https://www.ncbi.nlm.nih.gov/pubmed/23118540 http://dx.doi.org/10.2147/NDT.S36771 |